Compare MOVE & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOVE | DSGN |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 819.6M |
| IPO Year | 2021 | 2021 |
| Metric | MOVE | DSGN |
|---|---|---|
| Price | $20.00 | $10.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.25 |
| AVG Volume (30 Days) | 54.9K | ★ 957.8K |
| Earning Date | 04-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $433,000.00 | N/A |
| Revenue This Year | $1,460.71 | N/A |
| Revenue Next Year | $96.77 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $3.33 |
| 52 Week High | $34.87 | $17.25 |
| Indicator | MOVE | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 65.86 | 38.12 |
| Support Level | $6.27 | $9.25 |
| Resistance Level | $34.87 | $13.54 |
| Average True Range (ATR) | 2.38 | 1.39 |
| MACD | 0.69 | -0.54 |
| Stochastic Oscillator | 87.44 | 12.95 |
Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.